Sarai Sarvide
YOU?
Author Swipe
View article: Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics
Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics Open
View article: 179 | GENOMIC AND TRANSCRIPTIONAL SINGLE‐CELL HETEROGENEITY IN GERMINAL‐CENTER LYMPHOMAS: INSIGHTS INTO FOLLICULAR LYMPHOMA TRANSFORMATION
179 | GENOMIC AND TRANSCRIPTIONAL SINGLE‐CELL HETEROGENEITY IN GERMINAL‐CENTER LYMPHOMAS: INSIGHTS INTO FOLLICULAR LYMPHOMA TRANSFORMATION Open
View article: Supplemental Table 9 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 9 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Clinical characteristics of MM patients who develop SPM (n = 29) vs those who have not (n = 279). P-value is calculated using corrected χ2 for dichotomous variables, and Kruskal-Wallis for numerical variables.
View article: Supplemental Table 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Genetic relationship between mutant HPC and tumor cells.
View article: Supplemental Table 4 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 4 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Detected variants passing all filters categorized as pathogenic or likely pathogenic somatic mutations.
View article: Supplemental Table 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Key disease characteristics between patients with available (n = 308) and unavailable (n = 583) samples included and not included in this study from the GEM2012MENOS65, GEM-CESAR, and GEM-CLARIDEX trials. P-value is calculated using correc…
View article: Supplemental Table 5 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 5 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Quality control of the 555 NGS samples included in the study.
View article: Supplemental Table 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
List of genes included in the pan-myeloid targeted sequencing panel (SOPHiA GENETICS, Saint Sulpice, Switzerland).
View article: Supplemental Table 8 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 8 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Hematologic toxicity during treatment observed in patients enrolled in the GEM2012MENOS65, GEM-CLARIDEX and GEM-CESAR clinical trials compared to mutant HPC detected at baseline. P-value is calculated using corrected χ2 test.
View article: Supplemental Figure 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 3 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Overall survival (OS) according to the top four frequently mutated genes at diagnosis: (A) DNMT3A, (B) TET2, (C) ASXL1, and (D) STAG2 in untreated patients enrolled in the GEM2012MENOS65 and GEM- CLARIDEX trials with BM HPC samples.
View article: Supplemental Figure 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 2 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Genetic relationship between mutant HPC and tumor cells. Concordance between the mutational landscape of hematopoietic progenitor cells (HPC) and patient-paired tumor cells (n = 42) used as filtering criteria for mutations observed in RAS …
View article: Supplemental Table 7 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 7 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Clinical and tumor microenvironmental characteristics of untreated, newly diagnosed active MM patients having normal (n = 129) vs mutant HPC (n = 38). P-value is calculated using corrected χ2 for dichotomous variables, and Krusk…
View article: Supplemental Table 6 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Table 6 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Mutational landscape of HPC according to a variant allele frequency (VAF) ≥2% among untreated patients with MM. Frequencies are calculated according to all patients with BM HPC at diagnosis (n = 232).
View article: Supplemental Figure 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Supplemental Figure 1 from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Overview illustrating a graphical representation of gating strategy used to detect bone marrow CD34+ hematopoietic progenitor cells (HPC) and plasma cells (PCs) using fluorescence activated cell sorting (BD FACSDiva v 8.0.2). Panels show b…
View article: Data from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma
Data from Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma Open
Mutant hematopoietic progenitor cells (HPC) may expand under high-dose melphalan- and lenalidomide-based regimens and give rise to hematologic second primary malignancies (SPM) in multiple myeloma. To determine whether genetic screening of…
View article: Unravelling the molecular activation of the reparative cardiac fibroblasts after myocardial infarction
Unravelling the molecular activation of the reparative cardiac fibroblasts after myocardial infarction Open
Activated cardiac fibroblasts ( Postn + CFs) are responsible for the healing of the heart tissue after a myocardial infarction (MI). However, so far little is known about the moment that CFs are activated, and the genes involved in this pr…
View article: Bone Marrow Spatial Transcriptomics Reveals a Myeloma Cell Architecture with Dysfunctional T-Cell Distribution, Neutrophil Traps, and Inflammatory Signaling
Bone Marrow Spatial Transcriptomics Reveals a Myeloma Cell Architecture with Dysfunctional T-Cell Distribution, Neutrophil Traps, and Inflammatory Signaling Open
The bone marrow (BM) is a complex tissue where spatial relationships influence cell behavior, signaling, and function. Consequently, understanding the whole dynamics of cellular interactions requires complementary spatial techniques that p…
View article: Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance Open
View article: Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia Open
Failure to achieve complete response (CR) and persistence of measurable residual disease (MRD) are associated with inferior survival in acute myeloid leukaemia (AML).1 Poor outcomes are attributed to primary chemotherapy resistance, as wel…
View article: The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes Open
Myelodysplastic syndromes (MDS) are hematopoietic stem cell (HSC) malignancies characterized by ineffective hematopoiesis, with increased incidence in older individuals. Here we analyze the transcriptome of human HSCs purified from young a…
View article: Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia Open
Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workups. We hypothesized that the mutational …
View article: Preneoplastic somatic mutations including <i>MYD88</i> <sup>L265P</sup> in lymphoplasmacytic lymphoma
Preneoplastic somatic mutations including <i>MYD88</i> <sup>L265P</sup> in lymphoplasmacytic lymphoma Open
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the B lineage in elderly individu…
View article: FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology Open
Large-scale immune monitoring is becoming routinely used in clinical trials to identify determinants of treatment responsiveness, particularly to immunotherapies. Flow cytometry remains one of the most versatile and high throughput approac…
View article: Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development Open
Although light-chain amyloidosis (AL) and multiple myeloma (MM) are characterized by tumor plasma cell (PC) expansion in bone marrow (BM), their clinical presentation differs. Previous attempts to identify unique pathogenic mechanisms behi…
View article: Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients
Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients Open
Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune response…
View article: Immunologic characterization of COVID-19 patients with hematological cancer
Immunologic characterization of COVID-19 patients with hematological cancer Open
Not available.
View article: Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance
Immunologic Characterization of Coronavirus Disease 2019 (COVID-19) Patients with Hematological Cancer: Biologic and Clinical Significance Open
Background: The immune system reacts to viral infection with cellular and humoral responses. Thus, myelo- and lympho-suppression caused by cancer itself as well as cytotoxic treatment may pose a challenge to COVID-19 patients with solid an…
View article: Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma Open
Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later have inferior progression-free survival (PFS). This questions the legitimacy of…
View article: Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma Open
Granulocytic myeloid-derived suppressor cells (G-MDSCs) promote tumor growth and immunosuppression in multiple myeloma (MM). However, their phenotype is not well established for accurate monitoring or clinical translation. We aimed to prov…
View article: Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma Open
Risk of developing myelodysplastic syndrome (MDS) is significantly increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that it is therapy independent. However, the incidence and sequel…